多肿瘤标志物蛋白芯片检测系统在临床应用中的评价  

Evaluation of clinical application of detection system of multi-tumor markers protein chip

作　　者：李心河[1] 单宁宁[1] 高扬[1] 王惠敏[1] 刘延红[1] 夏洪印[1] 邹雄[1] 侯明[2] 

机构地区：[1]山东大学齐鲁医院检验科,山东济南250012 [2]山东大学齐鲁医院血液科,山东济南250012

出　　处：《检验医学》2009年第7期523-526,共4页Laboratory Medicine

摘　　要：目的评价多肿瘤标志物蛋白芯片在健康人群的普查、肿瘤的早期诊断及监测预后的应用。方法使用C-12型多肿瘤标志物蛋白芯片检测系统(C-12)测定分析8330例恶性肿瘤患者、9657例良性疾病患者和23531名健康体检者血清12种常见肿瘤标志物:甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原242(CA242)、糖类抗原125(CA125)、糖类抗原153(CA153)、神经元特异性烯醇化酶(NSE)、前列腺特异性抗原(PSA)、游离前列腺特异性抗原(f-PSA)、铁蛋白(FER)、β-人绒毛膜促性腺激素(β-HCG)和人生长激素(HGH)。结果C-12对健康人群肿瘤的检出率为7.03%,恶性肿瘤组的阳性率达85.6%。结论运用C-12联合检测多种肿瘤标志物可以提高恶性肿瘤诊断的敏感性,可应用于预后及疗效观察,对肿瘤高危人群的普查具有一定的指导意义。Objective To evaluate the clinical application of C-12 multi-tumor markers protein chip （C-12） in healthy population census, early diagnosis in tumors and monitoring prognosis. Methods The serum levels of 12 tumor markers, including carbohydrate antigen 199 （ CA199 ）, neuron-specific enolase （ NSE ）, carcinoembryonic antigen （ CEA）, carbohydrate antigen 242 （ CA242 ）, carbohydrate antigen 125 （ CA125 ）, carbohydrate antigen 153 （ CA 153 ）, alpha fetoprotein（ AFP）, ferritin （ FER ）, free prostate specific antigen （ f-PSA ）, prostate specific antigen （ PSA ）, human chorionic gonadotropin （β-HCG） and human growth hormone （ HGH）, were determined in 8 330 malignant tumor patients,9 657 patients with benign disease and 23 531 healthy controls by C-12 system. Results The positive rates determined by the C-12 system in malignant tumor patients were 85.6% and 7.03% in healthy population. Conclusions Combined measurement of multiple serum tumor markers can significantly increase the diagnostic sensitivity for malignant tumor, and be used as an earlier tumor-screening tool to asymptomatic people, especially to the high risk people.

关 键 词：肿瘤标志物 蛋白芯片 化学发光分析 

分 类 号：R446.61[医药卫生—诊断学]